Retrospective Study
Copyright ©The Author(s) 2023.
World J Cardiol. Jan 26, 2023; 15(1): 1-12
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.1
Table 3 The results of VSA-related parameters in the 2 groups

Group D
Group F
P value
Medications taken before CAG
       Calcium-channel blocker (%)11 (20)16 (48)0.01
       Long-acting nitrate (%)6 (11)9 (27)0.05
       Statins (%)26 (48)9 (27)0.05
       Anti-platelet therapy (%)14 (26)9 (27)0.89
VSA-related symptom
       Cold sweating or syncope (%)5 (9) 4 (12)0.67
CAG.SPT
       Coronary atherosclerosis (%)28 (52)25 (76)0.03
       MB (%)7 (13)10 (30)0.05
       Multi-vessel spasm (%, n)32 (74, 43)19 (66, 29)0.42